Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
AusperBio Therapeutics Inc.
AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies
August 27, 2026
AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171
August 3, 2026
AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
December 13, 2025